Ignite Creation Date:
2024-05-06 @ 12:29 PM
Last Modification Date:
2024-10-26 @ 12:59 PM
Study NCT ID:
NCT03775746
Status:
UNKNOWN
Last Update Posted:
2020-02-12
First Post:
2018-12-12
Brief Title:
Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy DAPT Improve Thrombotic Status in Acute Coronray Syndrome ACS ACS
Sponsor:
East and North Hertfordshire NHS Trust
Organization:
East and North Hertfordshire NHS Trust
Study Overview
Official Title:
Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy DAPT Improve Thrombotic Status in Acute Coronray Syndrome ACS ACS
Status:
UNKNOWN
Status Verified Date:
2020-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VaLiDate-R
Brief Summary:
A prospective randomised open label study of 3 clinically licensed treatments for ACS to assess the effects of these treatments on blood tests of endogenous fibrinolysis 50 patients will be randomised to each of the 3 treatment arms in 111 ratio Patients will receive the randomised treatment for 1 month after their index admission with ACS
Detailed Description:
Heart attacks are caused by a blood clot occurring in a blood vessel artery which supplies blood to the heart Such a clot can build up and block the blood flow depriving part of the heart muscle of oxygen and blood causing transient or permanent damage to the heart muscle
The standard treatment for a heart attack is two blood thinning medications combined every day to reduce the risk of further blood clots forming and to prevent another heart attack The highest risk of another heart attack is in the next 30 days after the first heart attack
However despite two blood thinners combined some patients still go on to have another clot heart attack or stroke or death and this can be life threatening Earlier research has shown that through a blood test it is possible to identify patients who remain at increased risk of further clots and who may benefit from further blood thinners to reduce the risk of further heart attack stroke and death in the next 30 days
The aim of this study is to test which of 3 blood thinning treatment options all already in widespread clinical use is best for patients to reduce further blood clots in particular the addition of low dose rivaroxaban
The standard treatment for a heart attack is two blood thinning medications combined every day to reduce the risk of further blood clots forming and to prevent another heart attack The highest risk of another heart attack is in the next 30 days after the first heart attack
However despite two blood thinners combined some patients still go on to have another clot heart attack or stroke or death and this can be life threatening Earlier research has shown that through a blood test it is possible to identify patients who remain at increased risk of further clots and who may benefit from further blood thinners to reduce the risk of further heart attack stroke and death in the next 30 days
The aim of this study is to test which of 3 blood thinning treatment options all already in widespread clinical use is best for patients to reduce further blood clots in particular the addition of low dose rivaroxaban
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None